Today’s #trialtuesday is led by Alok Tewari of Dana-Farber Lank Center for Genitourinary Oncology. #CCTI_DFCI presents Trial 23-643: USP1 inhibitor for BRCA 1/2, PALB2, RAD51C/D mutated or HSD positive solid tumors. Now in dose escalation. @DanaFarber Dana-Farber News
Visit: forms.office.com/r/kM7e6JVxre

For #TrialTuesday , Brian Van Tine Washington U. Med leads Alliance for Clinical Trials in Oncology A092104, a trial for patients with advanced uterine #leiomyosarcoma after chemotherapy has stopped working. To learn more, visit bit.ly/Alliance-A0921… #NCI #NCTN Nat'l LMS Foundation Sarcoma Alliance

📣I am looking for around 30 participants to take part in my research project. If you have #T1DM or #T2DM and you would like to receive a self-compassion intervention, please sign up at: cccusocialsciences.az1.qualtrics.com/jfe/form/SV_aW… #GBDoc #ScotDoc #NIDoc #DClinPsy #DiabetesResearch #TrialTuesday

For #trialtuesday , #CCTI_DFCI presents new trial 23-600 led by Filipa Lynce, MD, FASCO. IDE161, a PARG inhibitor, targets HRD and BRCA mutations in ER+ breast, endometrial, colorectal, and head and neck with these mutations. Different from PARPi. Dana-Farber
Visit: forms.office.com/r/kM7e6JVxre

#trialtuesday is Trial 23-044: STX-478 mutant-selective, PI3Kα small molecule inhibitor, highly selective for kinase and/or helical domain mutations in breast, gynecological, head and neck, and other solid tumors #CCTI_DFCI Dana-Farber Antonio Giordano, MD PhD
Visit: forms.office.com/r/kM7e6JVxre

Thanks Pete for always having a welcoming, feel, and a hot meal after a long day in trial! Love this place love this team! @stpetes_dancingmarlin @pazotos #Tuesday Trial #Trial Tuesday #Tuesday #Trial #BeGreat #GetAfterIt #lfg

#TrialTuesday : Kayvan (Kevin) Zarrabi, MD MS is leading a first-in-human trial evaluating the safety, efficacy, & tolerability of the PARG inhibitor IDE161 as a monotherapy in metastatic solid tumors harboring BRCA1/2 mutations or other HR defects now enrolling at SKCC: jeffersonhealth.org/clinical-speci…

If you're over 18 and living with #diabetes , you could take part in a #research study run by David Hohenschurz at The UCO Imperial College London , who is testing a new medication-free treatment, called NeuOst, for nerve pain in the feet👣 #TrialTuesday

Participants Wanted⤵️
If you have #Type1 or #Type2 Diabetes and you would like to take part in a research project offering Compassionate Mind Training, please sign up here: cccusocialsciences.az1.qualtrics.com/jfe/form/SV_aW…
Please RT Diabetes UK Research JDRF Research
#GBDoc #DiabetesResearch #TrialTuesday

If you're over 18, living with #diabetes and have had foot ulcers, you could take part in a study run by researchers at University of Brighton, exploring how and why people choose dressings for their feet.👣 #TrialTuesday 🧵

If you're over 18 and living with #Type2Diabetes , you could take part in a home-based insulin trial in part of the project @trialsathome 🏘️ who are testing remote studies as a way to involve more people in #research .📣 #TrialTuesday IDFEurope / Diabetes Ken Tait

Just like a well-crafted case, let's approach this Tuesday with precision and finesse.

Ready to strengthen your legal practice? Contact us today at (877) 631 – 9711.

#InstaAnswer #TrialTuesday #CustomerService

We know your time is valuable, and every call is crucial. That's why Insta Answer is here to ensure you never miss an opportunity to represent justice!

Contact us at (877) 631 – 9711 and let's make your legal practice a winning one!

#InstaAnswer #TrialTuesday #CustomerService

#APPROACHtrial is recruiting from several hospitals in Yorkshire – exploring whether a support package including a mobile app can help cancer patients to walk more. To find out more go to → tinyurl.com/approach-leafl…

#TrialTuesday #proudtodiscover @barnsleyrd

Peter Navarro, second ex-Trump aide to be prosecuted for contempt of Congress, faces trial Tuesday

#PeterNavarro
#ExTrumpAide
#ContemptOfCongress
#TrialTuesday

Former White House trade adviser Peter Navarro goes on trial Tuesday as the second ex-aide to former Presi

Only canola, corn, an intercropping trial, and a few oat and triticale plots left for #harvest23 . We're about 85-90% complete! Bring on the sunshine!

#TrialTuesday #AgResearch #plots #ABAg #GRO

The last of the trials is processed! Data is being analyzed. Results will be available to members & by searching the website over the next month or so. If you're looking for something in particular, email [email protected].

#GRO #AgResearch #TrialTuesday #RDAR

This #TrialTuesday , learn about Mayo Clinic's phase II trial studying how well vismodegib and focal adhesion kinase (FAK) inhibitor GSK2256098 work in treating patients with #meningiomas that progress or grow back after treatment.
mayocl.in/48Qh9me
Dr. Alfredo Quiñones-Hinojosa Alliance for Clinical Trials in Oncology

This week's #TrialTuesday evaluates the safety and feasibility of tumor treating fields (TTF) produced by the portable Novo TTF-200T device to treat spinal #leptomeningeal disease in patients with #breastcancer that has metastasized.
mayocl.in/3uOVyMW
Dr. Alfredo Quiñones-Hinojosa Novocure

This week's #TrialTuesday examines the pharmacological effects of patient uptake and tolerance of the compound BI 907828, an MDM2 inhibitor that is being developed to treat newly diagnosed #glioblastoma .
mayocl.in/4ckH6gK
Dr. Alfredo Quiñones-Hinojosa Boehringer Ingelheim